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Two stage instrumental variable methods are commonly used to estimate the causal effects of
treatments on survival in the presence of measured and unmeasured confounding. Two stage
residual inclusion (2SRI) has been the method of choice over two stage predictor substitution
(2SPS) in clinical studies. We directly compare the bias in the causal hazard ratio estimated by
these two methods. Under a principal stratification framework, we derive a closed form solution
for asymptotic bias of the causal hazard ratio among compliers for both the 2SPS and 2SRI
methods when survival time follows the Weibull distribution with random censoring. When there
is no unmeasured confounding and no always takers, our analytic results show that 2SRI is
generally asymptotically unbiased but 2SPS is not. However, when there is substantial
unmeasured confounding, 2SPS performs better than 2SRI with respect to bias under certain
scenarios. We use extensive simulation studies to confirm the analytic results from our closedform solutions. We apply these two methods to prostate cancer treatment data from SEERMedicare and compare these 2SRI and 2SPS estimates to results from two published randomized
trials

Keywords
instrumental variable; two-stage residual inclusion; two-stage predictor substitution; unmeasured
confounding; survival; bias
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1. Introduction
Evaluating the effectiveness of treatment and identifying the causal relationship between
exposure and disease are critical objectives for clinical and health services researchers.
Confounding is often a concern when analyzing nonrandomized observational studies and
even randomized studies with non-compliance [1]. Instrumental variable (IV) methods are
increasingly being used in clinical comparative effectiveness studies to potentially control
for both measured and unmeasured confounding. Angrist et al.[2] defined the IV for causal
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effects of treatment on outcome to be a variable satisfying the following five assumptions: i)
The potential outcomes on one subject are unrelated with the particular assignment of
treatment to the other subjects; ii) IV is randomly (or ignorably) assigned; iii) Any effect of
IV on the outcome must be mediated by treatment received (the exclusion restriction);iv) IV
has nonzero effect on treatment received; v) There are no defiers. (for details see section 2)

Author Manuscript

In a recent clinical study, we were interested in comparing the effectiveness of two
treatments for prostate cancer in elderly men using SEER-Medicare, a large national
observational database. Specifically, we planned to use IV methods to estimate the effect of
the addition of external beam radiation therapy (EBRT) to androgen suppression therapy
(ADT) in improving overall survival in men with locally advanced prostate cancer. We
considered a commonly used IV in health services research: local area treatment patterns
defined by the percentage of active treatment in hospital referral regions (HRR). This IV has
been shown to capture regionally distinct structural variation in care [3]. Such variation is
not fully explained by patient characteristics. Further, this IV varies across HRRs and is
strongly associated with treatment assignment. Finally, it is balanced across important
observed prognostic factors. Although there is an extensive literature on the importance of
choosing an appropriate instrument, less attention has been paid to using the appropriate
modeling approach once an IV is selected.

Author Manuscript

Recently, there has been rapid uptake and widespread use of two IV based analytic
approaches called two-stage residual inclusion (2SRI) and two-stage predictor substitution
(2SPS)[4, 5]. These methods have been used to correct for bias due to endogeneity in nonlinear models for both binary and time-to-event outcomes. Among these two IV approaches,
2SRI was shown to consistently estimate a conditional causal parameter under certain
assumptions [4] and has been adopted as the method of choice in clinical research studies
involving survival outcomes[6, 7, 8]. The conditional causal parameter that Terza et al.[4]
consider is only identified by making homogeneity assumptions that go beyond the five
assumptions for a valid IV defined in the first paragraph. Angrist et al. [2] showed that under
these five assumptions for a valid IV, the only treatment effect that is identified is the
average treatment effect for the compliers, where the the compliers are the subjects who
would take the treatment if encouraged to do so by the IV but would not take the treatment if
not encouraged by the IV; this is called the local average treatment effect (LATE). In the
context of a binary outcome, Cai et al.[5] demonstrated that both the 2SRI and 2SPS
methods generated biased estimates of LATE among compliers for binary outcome. In this
paper, we focus on the properties of 2SPS and 2SRI as estimators of the LATE for time-toevent data.

Author Manuscript

Despite the fact that there is growing interest in applying two stage IV methods to time-toevent data, little is known about the potential bias of using such methods to estimate LATE
among compliers. We derive closed form expressions of the bias and conduct extensive
simulations to quantify this bias. We then apply both of the two-stage IV methods to our
prostate cancer treatment data and compare them to the results from two published
randomized clinical trials [9, 10]
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2. Notation, Assumptions, Compliance Categories, and Model
2.1. Notation
Following the notation of Cai et al.[5] and Nie et al.[11], an N-dimensional vector of binary
IV is represented by Ṟ. An IV value of 1 represents encouragement to receive the active
treatment and 0 represents no encouragement to receive the active treatment. In a RCT
setting, where the IV is the randomized assignment, then an IV value of 1 represents random
assignment to treatment and 0 represents random assignment to control; in the prostate
cancer observational study described in the introduction, an IV value of 1 represents a high
local area rate (above median) of adding EBRT to ADT and 0 represents a low local area
rate (below the median) of adding EBRT to ADT. The ith element Ri = 1 implies that subject
i is encouraged to receive the active treatment, whereas Ri = 0 indicates that subject i is not
encouraged to receive the active treatment. Let ẔṞ be an N-dimensional vector of potential

Author Manuscript

treatment received given Ṟ, and ith element

indicates that subject i receives the active

means that subject i receives the control under Ṟ.

treatment and

Similarly, we define ṮṞ,Ẕ to be an N-dimensional vector of potential survival time under Ṟ
and Ẕ, and ith element
is the potential survival time for subject i under Ṟ and Ẕ. Let
Ṟ
,
Ẕ
Ḻ
to be an N-dimensional vector of potential censoring time under Ṟ and Ẕ, and ith
is the potential censoring time for subject i under Ṟ and Ẕ.

element

We define YṞ
̱ , Ẕ=min{ṮṞ,Ẕ, ḺṞ,Ẕ}, the elementwise minimum of potential censoring and
survival times, to be an N-dimensional vector of potential observed follow up time under Ṟ
and Ẕ, and ith element

represents the potential follow up time for subject i under Ṟ
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and Ẕ. Let

indicates whether subject i is observed to terminate by

) or by censoring (
) given Ṟ and Ẕ. The vector Xi̱ represents
failure (
measured confounding variables for subject i.
2.2. Assumptions
The main assumptions we will make for causal modeling are the five assumptions made by
Angrist et al. [2], and a random censoring assumption for the survival setting.
1.

Stable Unit Treatment Value Assumption (SUTVA)[12, 13]
a.

Author Manuscript

b.

if

, then

if

and

, then

The SUTVA assumption says that the potential outcomes for subject i are
not related with the treatment status of other subjects such that we can write
,
,
,
,
as
,
,
,
,
respectively. The SUTVA assumption also implies the assumption of
consistency, such that the value of the potential outcome given a treatment
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remains unchanged no matter what the treatment assignment mechanism is
[12]
2.

Independence of the instrument Ṟ [14]:
Conditional on a vector of confounders X̱, the random vector (YṞ
̱ ,Ẕ, ṮṞ,Ẕ,ḺṞ,Ẕ,ẔṞ)
is independent of Ṟ. In a randomized trial where R is the IV, the independence
assumption holds without conditioning on X̱.

3.

Exclusion Restriction
∀Ẕ,Ṟ, and Ṟ′, we have:

ṮṞ,Ẕ=ṮṞ′,Ẕ,ḺṞ,Ẕ = ḺṞ′,Ẕ, YṞ′
̱ ,Ẕ = YṞ′
̱ ,Ẕ, This assumption implies that any effect of
IV on potential outcomes must be through its effect on treatment actually received.
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Thus, we can write
,
,
as
restriction and SUTVA assumptions.
4.

,

,

by combining the exclusion

Non-zero Average Causal Effect of Ṟ on Ẕ

This assumption means the IV is correlated with treatment received.
5.

Monotonicity [15]

Author Manuscript

This assumption rules out the existence of defiers. No subject always does the
opposite of the treatment assigned.
6.

Independent censoring
The distribution of potential survival time ṮṞ,Ẕ is independent of the distribution of
potential censoring time ḺṞ,Ẕ.

2.3. Compliance Categories

Author Manuscript

Under the framework of principal stratification and potential outcomes [2, 16], subjects in a
two-arm randomized trial can be categorized into 4 principal strata: Always takers (AT) are
subjects who always take the treatment regardless of assignments (Z1 = 1, Z0 = 1);
Compliers (C) are subjects who comply with their assignments (Z1 = 1, Z0 = 0); Never
takers (NT) are the subjects who never take the treatment no matter which group they are
assigned to (Z1 = 0, Z0 = 0); Defiers (D) are the subjects who take the treatment opposite of
their assignments (Z1 = 0, Z0 = 1).
2.4. Model
We first define the probability of receiving the treatment Pr(R = 1) = r, the probability of
being a always taker Pr(AT) = ρa, and the probability of being a complier Pr(C) = ρc. We
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also define the probability of being a defier Pr(D) = ρd, but under the monotonicity
assumption, there are no defiers so that ρd = 0. Hence, the probability of being a never taker
Pr(NT) is equal to 1 − ρa − ρc.
We assume both potential censoring time and potential survival time follow the Weibull
distribution with the same shape parameter α. The potential censoring time for the subjects
in each principal strata follows Weibull(α, λ), and we define the parameters of the
probability distribution of potential survival time for each principal strata as follows:

Author Manuscript

We also examined scenarios in which different shape parameters α’s are assumed for the
potential censoring time and the potential survival time. These details are given in Appendix
E. The density of Weibull distribution is f(t) = (α/K)(t/K)K−1exp(−(t/K)α) and the hazard rate
is h(t) = αK−αtα−1. In the case of Weibull regression with covariates X, K−α can be
reparameterized as exp(βX). The hazard rate for the compliers if treated is
. The hazard rate for the compliers if not treated is
. Hence, the log causal hazard ratio ϕ for the compliers is the
difference between two log hazard rates:

Author Manuscript

3. Two Stage Predictor Substitution (2SPS) Method
The 2SPS method is frequently used and simple to implement [4]. In the first stage, the
treatment received Z is regressed on the IV-treatment assignment R, and let P = E (Z∣R). In
the second stage, a log linear model including P, defined as:

Author Manuscript

is fitted to estimate the coefficient ξ. This is 2SPS estimator of the log causal hazard ratio.
We first derive a closed form expression to the probability limit of the maximal likelihood
estimator (M.L.E) of ξ, then take the difference between this probability limit and true log
causal parameter ϕ for the expression of the asymptotic bias of the 2SPS estimator as an
estimator of the log causal hazard ratio for compliers.
3.1. Probability limit of M.L.E of causal parameter
Let P̂ denote the predicted value from the estimated binary regression model. i.e., P̂ =
Ê(Z∣R). When P̂ is substituted for P, the second stage Weibull model becomes:
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Let ξ̂* and ξ̂ denote the estimators (M.L.E) of ξ* and ξ respectively. As sample size n → ∞,
P̂ → P,
, and
. Therefore,
. To derive closed form expression for the
asymptotic bias, we need to re-express ξ in terms of parameters specified in Section 2 under
the principal stratification framework.
Only always takers receive the treatment when assigned to control (R = 0). Both always
takers and compliers take the treatment when assigned to treatment (R = 1). Thus, it can be
shown that [5]:

Author Manuscript

Since P = {p0, p1} is an one-to-one transformation of R = {0, 1}, we have the following for
the second stage Weibull regression:
(1)

and,
(2)

Author Manuscript

Instead of working with a second stage model involving P, we can work with a model
involving R instead. Solving (1) and (2), we have:
(3)

The log linear model including R assumes two underlying Weibull distributions of the same
shape parameter α*, Weibull(α*, K0) and Weibull(α*, K1), for subjects assigned to control
(R = 0) and treatment (R = 1) respectively. Thus, (3) can be expressed as:

(4)

Author Manuscript

It is worth noting that both follow up times of subjects assigned to control, denoted as Y∣R =
0, and follow up times of subjects assigned to treatment, denoted as Y∣R = 1, actually follow
mixture distributions consisting of three different Weibull distributions. Details are given in
Appendix A. However, the second stage Weibull model of 2SPS method imposes the two
Weibull distributions, with the same shape parameter α* but different scale parameters K0,
K1, upon subjects assigned to treatment (R = 1) or assigned to control (R = 0) respectively.
Stat Med. Author manuscript; available in PMC 2016 June 30.
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Thus, the M.L.E of α*, K0, K1 are derived by maximizing the likelihood function Ln (α*,
K0, K1) that consists of products of two Weibull densities: Weibull(α*, K0) and Weibull(α*,
K1).

Author Manuscript

Let α̂* denote the M.L.E of α* and We set
, the
expectation of score equation derived from profile likelihood of α*, equal to 0 and let be
the solution. Under the assumptions stated in Section 2 and consistency of M.L.E, the
probability limit of the estimator α̂* is . Details are given in Appendix C. Once the
parameters of the principal strata are defined, can be solved numerically using a rootfinding algorithm such as the “bisection” method. Let K̂0, K̂1 be the M.L.Es of the two scale
parameters K0, K1 respectively. After the value of is determined, the probability limits of
the estimators K̂0, K̂1 can be derived as follows:

(5)

and,

(6)

Author Manuscript

The detailed steps of the derivation of (5) and (6) are given in Appendix C. By substituting
(5) and (6) into (4), we derive the expression of log causal hazard ratio ξ as the following:

(7)

Author Manuscript

Thus, (7) is the closed-form expression of the probability limit of the log causal hazard ratio
estimator ξ̂* from the 2SPS Weibull model.
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The asymptotic bias of the causal parameter ξ of the 2SPS Weibull regression model is
simply the difference between the true log causal hazard ratio ϕ and the derived closed form
expression of ξ, such that
(8)

We can re-paramterize

in (8) with one additional parameter
as the following:
(9)

Author Manuscript

Δ in (9) is the log hazard ratio between never takers and compliers given no treatment. It can
be interpreted as the magnitude of the unmeasured confounding because the differences
between principal strata are attributable to the unmeasured confounding [5]. When Δ = 0 or
, there is no unmeasured confounding.
We make the following observations about the bias of 2SPS method from (3.11): 1) When α
= 1 and we treat α* as a known parameter and fix it at 1, that is the scenario when the
survival outcomes of all principal strata follow exponential distributions and we also fit an
exponential model in the second stage instead of estimating the shape parameter for a more
general form of Weibull distribution; 2) When ρc = 1, every subject is a complier and (8) can

Author Manuscript

. Then we have
. Setting ρc = 1, ρa = 0,
be simplified as
and ρn = 0, (8) becomes 0 so that bias B2sps = 0 when a randomized controlled trial has
perfect compliance; 3) When there is no causal effect (

), all terms in (8) cancel out

and we have B2sps = 0; 4) When ρa = 0 and
, there is no confounding because there are
no always takers and never takers can’t get treatment so that the confounding can only be
attributable to the difference between never takers and compliers given no treatment[5].
However, (8) can not be reduced to 0 under this setting so that the bias of 2SPS method
B2sps is generally not 0 even when there is no confounding. 5) λ, the scale parameter of the
censoring distribution is involved in bias equation (9), which coincides with the results in
Struthers and Kalbfleisch[17].
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We can analyze how parameters influence the relationship between the magnitude of
confounding and bias using derived closed form expression (9). For the purpose of
demonstration only, here we create four scenarios in which there are no always takers. The
results are revealed in Figure 1 (a)-(d).
In Figure 1, we can clearly see that the bias of the 2SPS method is not 0 when there is no
confounding. The bias increases with the larger shape parameter α of the survival function
(within each principal stratum). The bias is the smallest when we have an decreasing hazard
rate (α < 1) and the highest when we have an increasing hazard rate (α > 1). By comparing
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Figure 1 (a) and (b), we also observe that the bias decreases as the compliance rate increases
from 0.5 to 0.8. When the scale parameter (θc) is smaller, the bias is also smaller (Figure 1
(a) vs. (c)). Although the probability of being randomly assigned to the treatment group is
involved in computing the shape parameter of the second stage Weibull regression model,
its effects on the bias are very small (compare Figure 1 (b) to (d)).

4. Two Stage Residual Inclusion (2SRI) Method
Similar to the 2SPS method, the 2SRI method involves two stage modeling [4]. In the first
stage, we regress the treatment received Z on the IV-treatment assignment R and calculate
the residual term E = Z − E (Z∣R). In the second stage, we fit a log linear model on both
treatment received variable Z and residual E as,
(10)

Author Manuscript

, to estimate the regression coefficient λ1. This is 2SRI estimaor of the log causal hazard
ratio. We derive the probability limit of the M.L.E of λ1 first and then calculate the
asymptotic bias by taking the difference between this probability limit of the estimator and
true log causal hazard ratio among compliers.
4.1. Probability limit of M.L.E of causal parameter

Author Manuscript

As discussed in a previous study[5], (10) is not the true model for the hazard function h(Y∣Z,
E). In fact the true model includes the interaction term between Z and E. However, deriving
the closed-form expression for the probability limit of the estimator from (10) is very
difficult when (10) is not the true model. With one additional assumption that there are no
always takers, (10) becomes the true model. We derive a closed-form expression of the
probability limit of the estimator of causal parameter λ1 assuming that there are no always
takers and thus (10) is the true model. Let Ê denote the residuals from the estimated binary
regression model in the first stage. i.e., Ê = Z − Ê(Z∣R). When Ê is substituted for E, (10)
becomes:

Let

and λ̂1 be the estimators (M.L.E) of

and λ1. As sample size n → ∞, Ê → E,

Author Manuscript

, and
. Thus,
. To derive a closed form expression for the
asymptotic bias, we need to first re-express λ1 in terms of the parameters specified in section
2.3 under the principal stratification framework.
As shown in a previous study[5], under the no always taker assumption, the first stage
binary regression is E(Z∣R) = ρa + ρcR and residual term E = Z − E (Z∣R), thus the residual
term can be re-expressed as E = Z − ρa − ρcR. Since {Z, E} has an one to one relationship
with {Z, R}, we can establish the following equivalence between the model involving {Z, E}
and the model involving {Z, R} for the second stage Weibull model:

Stat Med. Author manuscript; available in PMC 2016 June 30.

Wan et al.

Page 10

Author Manuscript

(11)
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Under the no always taker assumption, the second stage Weibull regression model defined
by (10) assumes the three underlying Weibull distributions with the same shape parameter
but different scale parameters for subjects in the three different subgroups: 1) ~ Weibull(α*,
K0) for those who are assigned to treatment and receive the treatment actually (Z = 1, R = 1).
Only compliers are in this group; 2) ~ Weibull(α*, K1) for those who are assigned to
treatment but do not receive the treatment actually (Z = 0, R = 1), This group has only never
takers; 3) ~ Weibull(α*, K2) for those who are assigned to control and do not receive the
treatment (Z = 0, R = 0), both never takers and compliers are in this group. There are no
subjects that are assigned to control but still take the active treatment (Z = 1, R = 0) under
the assumption of no always takers. Thus, the M.L.E of α*, K0, K1, K2 are derived by
maximizing the likelihood function Ln(α*, K0, K1, K2) that consists of products of three
Weibull densities: Weibull(α*, K0), Weibull(α*, K1), and Weibull(α*, K2).

Author Manuscript

Let α̂* denote the M.L.E of α* and set
,
the expectation of score equation derived from profile likelihood of α*, to 0 and let be the
solution. Under the assumptions stated in section 2 and consistency of the M.L.E, the
probability limit of the estimator α̂* is . Details are given in Appendix D. With the
parameters of principal strata defined, can be solved numerically using a root-finding
algorithm. Let K̂0, K̂1, K̂2 be the M.L.Es of two scale parameters K0, K1, K2. Once the value
of is determined, we compute the probability limits of the estimators K̂0, K̂1, K̂2 as
follows:

(12)

and

Author Manuscript

(13)

and
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(14)

The derivation of (12),(13) and (14) is detailed in Appendix D. Based on (11), we can
establish the following three equations with all possible combination of values of Z and R
excluding the always takers scenario (Z=1, R=0).
1.

When Z=1 and R=1, there are only compliers in this subgroup.

Author Manuscript

(15)

2.

When Z=0 and R=1, there are only never takers in this subgroup.

(16)

Author Manuscript

3.

When Z=0 and R=0, there are mixture of both never takers and compliers in this
subgroup.

(17)

Author Manuscript

We then derive the closed form expression for the causal parameter λ1 by solving (15),(16),
and (17) for λ1 as follows:
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4.2. Bias analysis
To compute asymptotic bias of the 2SRI method, we subtract the true log hazard ratio ϕ
from the closed-form expression of λ1.
(18)

Author Manuscript

We can re-parameterize
in (18) in the way as in Section 3 and let
. From the
derived expression of asymptotic bias of 2SRI estimator, we can make the following
observations: 1) When α = 1, the survival outcome within a principal stratum follows an
exponential distribution. If we treat α* as known and set α* = 1, it means we fit an
exponential regression model in the second stage; 2) When there is perfect compliance (ρc =
1), we have B2SRI = 0. In this scenario,
. By plugging ρc = 1 into (18), we can easily
verify the results; 3) When there is no confounding (

), B2SRI = 0; 4) When there is no

), B2 SRI is not 0; 5) λ, the scale parameter of the censoring distribution
causal effect (
is involved in bias equation (18), similar to the findings for 2SPS method.

Author Manuscript

We can analyze how parameters influence the relationship between the magnitude of
confounding and bias from the 2SRI method using (18). Similar to the previous section, four
scenarios were created assuming there are no always takers. The results are shown in Figure
2 (a)-(d). In Figure 2, it is apparent that the bias of the 2SRI method is 0 when there is no
confounding. Intuitively, under the condition of no confounding, substituting the term of the
estimated residuals in the second stage survival model has no effect on the estimate of the
causal parameter. By comparing Figure 2 (a) and (b), we also observe that the bias decreases
as the compliance rate increases from 0.5 to 0.8. When the scale parameter (θc) is smaller,
the bias tends to be smaller (Figure 2 (a) vs. (c)). The probability of being randomly
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assigned to the treatment group has very small impact on the bias (compare Figure 2 (b) to
(d)).

5. Simulation
5.1. Simulation algorithm
We follow the five step algorithm used by Cai et al.[5] to generate data for a simulation
study. In the first step, a data set of N subjects is generated. Always takers, compliers, and
never takers among these subjects are generated from a multinomial distribution with
probabilities {ρa, ρc, ρn}. At the second step, treatment assignment status R is generated for
each subject with probability P(R = 1) = ρr. Because outcome in the present study is time to
event, we modified step 3 to generate potential survival time {T0, T1} and censoring time
{L0, L1} for each principal stratum based on the parameters

,

,

,

,

Author Manuscript

instance, if a subject is a complier, the potential time to death under control
from weibull (α,

) and the potential time to death under treatment

,

, λ. For
is generated

is generated from

weibull (α, ). The potential censoring time { , } are generated from weibull(α, λ). At
step 4, we use compliance status (always taker, complier, or never taker) and treatment
assignment status R to determine the treatment received status Z. For instance, if a subject is
a complier and assigned to treatment group (R = 1), then Z = 1. If a subject is an always
taker but assigned to the control group, then Z = 0. At step 5, the observed survival time and
censoring time are generated as follows:
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and finally observed follow up time and censoring indicator are given as:

5.2. Simulation results

Author Manuscript

To demonstrate the consistency between the derived closed form expressions and the
asymptotic biases from the 2SPS and 2SRI approaches under the assumption of no always
takers (ρa = 0), we ran the simulation 2000 times, with the sample size n=10000, according
to the same parameter settings presented in Figure 1 d) and Figure 2 d). Table 1 shows
simulation results from 4 scenarios (α = 0.5, 1, 1.5, 2). As shown in this table, the biases
from simulated results are consistent with the values computed with the derived analytic
formula for both the 2SPS and 2SRI Weibull models. We also considered 2SPS and 2SRI
Cox models (the second stage regression is a Cox model instead of a Weibull model). The
pattern of the biases from 2SPS and 2SRI Cox models remains the same as for the 2SPS and
2SRI Weibull models respectively. With decreasing hazard (α = 0.5), the bias from using the
2SPS approach is smaller than the bias from the 2SRI approach. When the hazard is constant
or increasing (α ≥ 1), the results are mixed. With stronger negative confounding, the 2SPS
method produces smaller bias than the 2SRI method. However, with no confounding or
stronger positive confounding, the 2SPS method produces larger bias than the 2SRI method.
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To evaluate the performance of both 2SPS and 2SRI methods in the setting where there are
always takers, we simulated the data with various combination of parameters based on the
following settings: i) Shape parameter α varies among {0.5, 1, 2}, which represent
decreasing, constant, and increasing hazard scenarios; ii) Probabilities of being always
takers ρa and compliers ρc were set to 3 combinations: {0.2, 0.7}, {0.7, 0.2}, and {0, 0.5}. In
this way, low, medium, and high levels of compliance were represented; iii) probability of
being assigned to treatment ρr were set to {0.1, 0.5} to reflect both new and relatively
established treatments; iv) Scale parameter of censoring distribution were set to {0.5, 1, 2};
v) Each of the parameters , , was set to {0.5, 1, 3} separately. Thus, 1458 possible
combinations were created. For each setting, we generated 10,000 observations and fit the
2SPS and 2SRI models to the data. This process was repeated 2000 times.
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The results are presented in Figure 3. The magnitude of bias increases with increasing
magnitudes of unmeasured confounding. As the value of shape parameter α increases, the
magnitude of bias increases. In the scenarios with decreasing hazard, the 2SPS method
outperforms the 2SRI method. The 2SRI method tends to have larger asymptotic bias when
the magnitude of unmeasured confounding is large. In the scenarios with constant hazard,
the 2SPS method slightly outperforms the 2SRI method when the magnitude of unmeasured
confounding is large. In the scenarios with increasing hazard, both approaches produce
larger biases. The 2SRI method performs better when the magnitude of unmeasured
confounding is small. When there are always takers, the 2SRI method could be biased even
when there is no measured confounding. We also compared the two methods using mean
square error and the conclusions remain the same (4).

6. Seer-Medicare Prostate Cancer Study
Author Manuscript
Author Manuscript

Prostate cancer is the highest prevalence non-skin malignancy among American men (In
2011, there were an estimated 2,707,821 men living with prostate cancer in the United
States. The number of deaths was 23.0 per 100,000 men per year). Unlike prostate cancers
that are diagnosed at an early stage, locally advanced prostate cancer is associated with
substantial morbidity and mortality. Radiation therapy is a common treatment for locally
advanced prostate cancer. Two randomized trials recently demonstrated that radiation
therapy reduces mortality for men with locally advanced tumors who also receive systemic
androgen deprivation[9, 10]. However, both trials excluded elderly patients and those with
early stage, PSA-screen detected cancer and therefore had less generalizability, a common
criticism of randomized evidence. Therefore, we applied two-stage IV methods to evaluate
survival outcomes in locally advanced prostate cancer, assessing survival outcomes of
androgen deprivation therapy with or without radiation therapy in comparison to the
randomized trials.
We analyzed data from the Surveillance, Epidemiology and End Results (SEER)-Medicare
database. The SEER-Medicare database links patient demographic and tumor-specific data
collected by SEER cancer registries to Medicare claims for inpatient and outpatient care. We
considered patients with prostate cancer diagnosed between January 1, 1995 and December
31, 2007 in SEER with follow up through December 31, 2010 in Medicare. The following
patients were excluded: 1) older than age 85; 2) with unknown urban category; 3) in hospital
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referral regions (HRR) with less than 50 patients; 4) with unknown distance to the closest
radiation facility; 5) patients who died within the first 9 months of the study. A total of
31,541 patients were selected and categorized as receiving androgen deprivation with or
without radiation therapy.
The cohort was divided into the following three groups: 1) patients with American Joint
Commission on Cancer (AJCC) Tumor stage (T-stage) of T2 or T3 and aged 65-75 (called
the RCT Cohort). The patients in the “RCT Cohort” are most comparable to the patients
from the two randomized studies of androgen deprivation with or without radiation
therapy[9, 10]; 2) elderly patients under-represented or excluded from the published
randomized trials with T-stage T2 or T3, aged 76-85 (called the “Elderly Cohort”); and 3)
patients with early stage, PSA-screen detected cancer with T-stage T1 disease who were
excluded from the published randomized trials (called the “Screen-Detected Cohort”).
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The study by Widmark et al.[9] included men from 47 centers in Europe diagnosed between
February, 1996 and December, 2002. 875 patients with locally advanced prostate cancer
(T3; 78%; prostate-specific antigen (PSA) ≤ 70 ng/mL; N0; M0) were enrolled. 439 patients
were randomly assigned to androgen deprivation alone and the other 436 patients received
androgen deprivation with radiation therapy. The study by Warde et. al. enrolled 1,205
patients with locally advanced (T3 or T4) prostate cancer, organ-confined disease (T2) with
either PSA >40 ng/mL or PSA >20 ng/mL and a Gleason score of 8 or higher between 1995
and 2005. 1205 patients were randomly assigned to receive the androgen deprivation alone
(n=602) or androgen deprivation with radiation therapy (n=603). The hazard ratios for
overall mortality reported previously [9] and [10] were 0.68 (95% CI 0.52–0.89) and 0.77
(95% CI 0.61–0.98). For ease of comparison, we combined the results of the randomized
trials using weighted-average meta-analysis. The meta-analytic HR was 0.73 (0.61–0.87).
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To assess the effectiveness of androgen deprivation with or without radiation therapy in
reducing overall mortality (death from any cause), we performed two-stage IV Weibull
regression analysis (2SPS and 2SRI) using a local area treatment rate instrument and
controlling for the propensity score. The local area treatment rate instrument was defined as
the proportion of patients who received definitive treatment (surgery or radiation therapy)
among all patients with prostate cancer in the hospital referral region (HRR) and we
categorized this instrument into a binary variable according to its median. This IV measures
the aggressiveness of local area treatment and captures regionally distinct structural care
variation not fully explained by patient characteristics. The IV was strongly associated with
treatment assignment and balanced important prognostic factors [3]. The propensity score
model included potential confounding variables including age, race, ethnicity, clinical T
stage, N stage, and World Health Organization tumor grade, 17 categories of co-morbid
disease, urban residence, and census track median income.
As shown in Table 2, there is variability in the estimated HRs obtained from the 2SPS and
2SRI methods. We estimated the shape parameter α ≈ 1.6 from the data. Using Figure 3, we
can see that the bias for both the 2SPS and 2SRI methods is the largest when we have an
increasing hazard (α > 1), even when the magnitude of unmeasured confounding is
relatively small. When the hazard function is a decreasing one (α < 1), the 2SPS method
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produces more stable and less biased estimates than the 2SRI method. In this case, 2SPS
may be a more appropriate approach to use. In the RCT Cohort, the estimated HRs
(HR=0.96) from both IV methods are much larger than the meta-analytic HR from the two
randomized studies. Note that the confidence intervals are also much larger in both IV
analyses than in the original RCTs. In the published RCTs, the authors concluded that there
was a statistically significant treatment effect (combined therapy is better) whereas from our
IV analysis, we can’t draw this conclusion. In the total study sample and separately in the
RCT Cohort and the Screen-Detected Cohort, the two IV estimates are quite similar.
However, for the Elderly Cohort, the estimate from the 2SPS method is different from the
estimate from the 2SRI method.

7. Discussion
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Many clinical and health services studies are using health care databases to compare the
treatment effectiveness for drug and surgical therapies, but are prone to unmeasured
confounding. Two stage IV methods have been gaining popularity among clinical
researchers because these methods provide a relatively simple approach to analyzing
survival outcome studies in the presence of unmeasured confounding. However, current
knowledge about potential bias in estimating the log causal hazard ratio is limited. As
demonstrated in our prostate cancer study, the large treatment effects estimated from two
stage IV methods could be attributable to potential bias. We have derived closed-form
expressions for the asymptotic bias of the 2SRI and 2SPS approaches assuming the survival
times follow a Weibull distribution with shape parameter α and scale parameter K. We have
demonstrated that these analytic results are consistent with our simulation results.
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For binary outcomes, two previous studies[5, 18] demonstrated that the bias in the treatment
effect estimated using the 2SRI approach increases as the magnitude of confounding
increases. In this current work, we have shown analytically and by simulation that the 2SRI
and 2SPS approaches are both biased in estimating the causal hazard ratio among compliers.
In some situations when the hazard is decreasing (e.g among patients who have recently
received a kidney transplantation), the 2SPS method is less biased than the 2SRI method and
could be a more appropriate method to use. When the hazard is an increasing function, both
IV methods may produce very large bias even under a moderate amount of unmeasured
confounding. In this case, we recommend exercising caution when interpreting results from
two-stage IV survival models.

Author Manuscript

We have shown that even when all IV assumptions are met, both the 2SRI and the 2SPS
methods could fail to consistently estimate the causal hazard ratio among compliers. Our
analytic results for bias may help to guide researchers in deciding when the bias is likely to
be reasonably small so that two stage IV methods may be reasonably applied. Furthermore,
in a sensitivity analysis approach, one may estimate the shape parameter and the censoring
proportion among patients assigned to treatment or control from the data. With the shape
parameter and censoring proportions fixed based on our known data the level of the
unmeasured confounding could be varied to examine how the estimates would change, as
shown in Figures 1 and 2. Alternative methods include partial likelihood estimation [19].
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Appendix
Appendix A: Mixture of Weibull Distributions
Prove the distribution function of observed survival time T conditional on random
assignment R can be expressed as the following equations:

(A.1)

and,
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(A.2)

In the above equations, AT represents always takers, C represents compliers, and NT
represents never takers. Other definitions of parameters and distributions that are used in the
proof are given below:
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no defiers under monotonicity assumption
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F(T∣R = 1) can be expressed as:
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F(T∣R = 0) can be expressed as:

Author Manuscript
Author Manuscript

Appendix B: Proofs related with Derivation of Closed Form Solution
1.

Assume survival time T ~ Weibull(α, K) and censoring time L ~ Weibull(α, λ). Let
Y = min(T, L) and δ = I(T ≤ L). Show that
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and,
(B.1)

Proof:
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Thus,
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2.

Assume survival time T is a mixture of three Weibull distributions with Density
. T1 ~ Weibull(α, K1), T2 ~ Weibull(α, K2), and T3 ~
. The censoring time L ~
Weibull(α, K3). The weights are p1, p2, p3 and
Weibull(α, λ). Let Y = min(T, L) and δ = I(T ≤ L). Show that
(B.2)
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Proof:
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3.

Given X follows a Weibull distribution (α*, K). Show that

Author Manuscript

(B.3)

Proof:
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4.

Given X follows a Weibull distribution (α*, K). Show that
(B.4)

Proof:
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5.

Given X follows a Weibull distribution (α*, K). Show that
(B.5)

Proof:
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6.
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Let Ti denote the survival time and Ci denote the censoring time for subject i. Ti
and Ci are independent. Ti ~ weibull(α, K), and Ci ~ weibull(α, λ). Let Yi = min(Ti,
Ci) denote observed follow-up time and δi be the indicator variable δi = (Ti ≤ Ci).
Show that:
(B.6)

Proof:
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Let

and use (B.1)
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Both E(Yi δi) and E(Yi) E (δi) have the same integral functions. Thus,

Similarly, we can establish the following:

Appendix C: Derivation of probability limits of M.L.E of α, K0, K1 for 2SPS
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Let Y = min(T, C) be observed follow-up time and δ = I(T ≤ C) be the censoring time. The
subjects are assigned to either treatment group (R = 1) or control group (R = 0). The
distribution of each subgroup has different scale parameter K but the same shape parameter
α*. Thus, likelihood function of observed follow up time Y can be written as:

Stat Med. Author manuscript; available in PMC 2016 June 30.

Wan et al.

Page 23

Author Manuscript

For treatment assignment group and control assignment group, subjects are from compliers
(c), never takers (nt), and always takers (at). Let nR1, nR0 denote number of subjects
assigned to treatment (R = 1) and control (R = 0). Let nR1, at, nR1, nt, nR1, c denote number of
always takers, never takers, and compliers that are assigned to treatment group. nR1, at +
nR1, nt + nR1, c = nR1. Let nR0, at, nR0, nt, nR0, c denote number of always takers, never takers,
and compliers, who are assigned to control group.nR0,at + nR0, nt + nR0, c = nR0. Therefore,
the likelihood can be rewritten as:
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Next, the log likelihood function is:
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To derive the M.L.E of K0, K1, take the first derivative of l(y) with respect to K0, K1 and set
score equation to 0, we have
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(C.1)

and,

(C.2)

To derive the M.L.E of α*, take the first derivative of l(y) with respect to α* and set score
equation to 0 and replace K1, K0 with the expressions (C.1) and (C.2), we have
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M.L.E α̂* is the solution to the above equation. Next, divide both sides by total number of
subject n, we have
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As nR1, nR0, nR1, at, nR1, nt, nR1, c, nR0, at, nR0, nt, nR0, c → ∞, the score equation converges to
the following:

(C.
3)
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Use the results from Appendix B, we can derive the following:
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and,
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Let

be the solution to the equation (C.3). By the consistency of M.L.E, Thus, we have
Next, substitute α̂* into equation (C.1)

Asymptotically, it converges to
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Similarly, K̂1 converges to
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Appendix D: Derivation of probability limits of M.L.E of α, K0, K1, K2 for
2SRI
Under the no AT assumption, we can find an expression for λ1 as follows. The first stage
regression can be re-expressed as following:
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Note that Z, E and Z, R are one-to-one correspondence. Knowing Z, E will let us know Z, R
and vice versa. Under no always taker assumption, we observe three subgroups 1) Z = 1, R =
1. Only compliers in this group; 2) Z = 0, R = 1, Only never takers in this group; 3) Z = 0, R
= 0, both never takers and compliers in this group. There are no patients that are assigned to
control but still takes on active treatment (Z = 1, R = 0). For the 3 subgroups, essentially we
are fitting 3 Weibull distributions with the same shape parameter α* and 3 different shape
parameter K0, K1, K2 with Weibull regression model: logh(t) = λ0 + λ1 Z + λ2 E
The likelihood function is:
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The log likelihood is:
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Take the first derivative of l(y) with respective to K0, K1, K2 respectively and set score
equation to 0, then we have

Author Manuscript

(D.1)

(D.2)

(D.3)
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Take the first derivative of l(y) with respective to α* and replace K0, K1, K2 with expression
(D.1),(D.2),(D.3), then we have:
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M.L.E α̂* is the solution to the above score equation. Next, divide the equation by total
sample size n,
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As sample sizes in each principal strata → ∞, the score equation will converge to:
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(D.
4)

where,
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is the solution to the equation (D.4). Thus,
can be derived as following:

. Probability limits of M.L.E of K0
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Similarly, for K1, K2,
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Appendix E: Assumption of the same shape parameter for survival and
censoring distributions
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In section 2 of the manuscript, we made the assumption that both time to event and
censoring time have the same shape parameter so that close form solution could be derived.
To evaluate the potential impact on the bias when the time to event and censoring time have
two different shape parameters and the assumption is violated, we re-evaluated the scenario
in the table 1 with the shape parameter α = 0.5. We set the shape parameter of censoring
distribution to be 1.2 and compared the differences. We found that the differences in bias of
2SPS between two scenarios ranges from 0.01 to 0.018 (δ varies from -2 to 2). For 2SRI
approach, the differences ranges from 0.001 to 0.13. These differences are attributable to the
different censoring proportions between two scenarios. The shape of relationship between
bias and δ remains approximately unchanged (data not shown). It should be noted that under
the assumption of having the same shape parameters for both survival time and censoring
time, the maximum likelihood estimator based on the survival likelihood that does not
incorporate the assumption of the shape parameters being the same is not fully efficient.
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Figure 1.

Plot of bias against magnitude of unmeasured confounding Δ using 2SPS method:(a) P (R =
1) = 0.8, ρa = 0, ρc = 0.5,

,

. (b) P (R = 1) = 0.8, ρa = 0, ρc = 0.8,

. (c) P (R = 1) = 0.8, ρa = 0, ρc = 0.5,

,

,

. (d) P (R = 1) = 0.5, ρa = 0,

ρc = 0.8,
,
. The different colour of solid line corresponds to different shape
parameter: black (α = 0.5), red (α = 1), and green (α = 2).
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Figure 2.

Plot of bias against magnitude of unmeasured confounding Δ using 2SRI method: (a) P (R =
1) = 0.8, ρa = 0, ρc = 0.5,

,

. (b) P (R = 1) = 0.8, ρa = 0, ρc = 0.8,

.(c) P (R = 1) = 0.8, ρa = 0, ρc = 0.5,

,

,

. (d) P (R = 1) = 0.5, ρa = 0,

ρc = 0.8,
,
. The different colour of solid line corresponds to different shape
parameter: black (α = 0.5), red (α = 1), and green (α = 2).
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Figure 3.

Absolute bias in estimating log causal hazard ratio using two stage IV methods (X-axis is
the magnitude of confounding Δ, Y-axis is the absolute bias). For 2SRI method or 2SPS
method, the biases computed for each of 1458 possible scenarios were grouped by the
magnitude of shape parameter α (decreasing hazard for α = 0.5, constant hazard for α = 1,
and increasing hazard for α = 2) and the magnitude of confounding Δ (larger values
represent lager confounding effects and 0 represents no confounding).
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Figure 4.

Mean square error in estimating log causal hazard ratio using two stage IV methods (X-axis
is the magnitude of confounding Δ, Y-axis is the Mean Square Error). For 2SRI method or
2SPS method, the mean square error computed for each of 1458 possible scenarios were
grouped by the magnitude of shape parameter α (decreasing hazard for α = 0.5, constant
hazard for α = 1, and increasing hazard for α = 2) and the magnitude of confounding Δ
(larger values represent lager confounding effects and 0 represents no confounding).
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0.177

0.116

0.055

-0.018

-0.097

-0.177

-0.247

0.101

0.075

0.051

0.026

0.007

-0.012

-0.039

-0.064

-0.091

-0.005

-0.030

-0.015

0.000

-0.028

-0.133

-0.326

-0.605

0.175

0.057

0.000

-0.007

0.000

-0.022

-0.110

-0.285

-0.545

0.261

0.114

0.029

0.000

0.000

-0.015

-0.086

-0.238

-0.477

-0.008

-0.033

-0.012

-0.004

-0.027

-0.134

-0.325

-0.607

0.176

0.053

0.000

-0.008

0.002

-0.025

-0.107

-0.284

-0.550

0.263

0.112

0.028

-0.003

0.002

-0.018

-0.087

-0.239

-0.476

-0.002

-0.027

-0.015

0.000

-0.029

-0.134

-0.326

-0.602

0.157

0.055

0.002

-0.009

0.000

-0.023

-0.112

-0.284

-0.544

0.236

0.108

0.029

-0.001

0.000

-0.014

-0.086

-0.235

-0.476

,

)
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0.769

-2

model;

0.770

0.701

0.605

0.479

0.320

0.115

-0.124

-0.360

-0.578

0.468

0.833

0.747

0.636

0.494

0.324

0.112

-0.122

-0.357

-0.571

0.531

-0.023

-0.069

0.059

-0.022

0.000

-0.034

-0.152

-0.362

-0.656

0.078

-0.026

-0.063

-0.056

-0.026

0.002

-0.036

-0.152

-0.359

-0.653

0.068

-bias computed via simulation for 2SRI Cox model;

-bias computed

-bias computed via simulation for 2SRI Weibull accelerated failure time

- bias computed via simulation for 2SPS Weibull accelerated failure time model;

-0.024

-0.069

-0.059

-0.026

0.003

-0.032

-0.153

-0.361

-0.656

0.075

- bias computed using analytic formula derived for 2SRI method;

- bias computed using analytic formula derived for 2SPS method;

0.698

-1.5

0.317

0

0.605

0.111

0.5

0.481

-0.122

1

-1

-0.359

1.5

-0.5

-0.574

2

via simulation for 2SPS Cox model;

2

0.467
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-2
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δ
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α
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Table 2
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Bias in estimating causal hazard ratio parameter for prostate cancer study
Outcome

Group

IV2sri

IV2sps

All cause mortality

Total (n=31541)

0.57(0.17-1.06)

0.59(0.19-1.09)

RCT Cohort (n=12924)

0.96(0.18-5.81)

0.97(0.18-5.94)

Elderly Cohort (n=14340)

0.74(0.20-1.83)

0.96(0.26-2.35)

Screen-Detected Cohort (n=4277)

0.34(0.02-2.99)

0.35(0.03-3.22)

Author Manuscript
Author Manuscript
Author Manuscript
Stat Med. Author manuscript; available in PMC 2016 June 30.

